Your Health, We Care
Another Name赛普替尼,塞尔帕替尼,Retevmo,LOXO-292,LuciSel
IndicationsFor the treatment of RET-positive advanced non-small cell lung cancer, thyroid cancer, and certain other cancers.
Reg No.09 L 1008/23
Inspection NO.2264-23
On May 8, 2020, Selpercatinib, as a prescription drug targeting the RET protein, was the first to be approved by the U.S. Food and Drug Administration (FDA). Use only as directed by a physician.
RET protein
The dosage of selpercatinib should be adjusted according to the patient’s actual condition. For specific details, please consult a doctor and strictly follow medical advice.
Recommended Reading: Dosage and Administration of Selpercatinib (Retevmo)
Common side effects: Diarrhea, fatigue, dry mouth, etc.
Serious side effects: Liver problems, lung problems, hypertension, etc.
Reference Article: Side Effects of Selpercatinib (Retevmo)
Pregnancy:
Your doctor will perform a pregnancy test before you start treatment with selpercatinib.
You should use effective contraception during treatment and for 1 week after the last dose of selpercatinib.
Lactation:
It is not known whether selpercatinib passes into breast milk.
Do not breastfeed during treatment with selpercatinib and for 1 week after the last dose.
1. Patients should be informed that hepatotoxicity may occur. If any signs or symptoms related to hepatotoxicity appear, contact a healthcare professional immediately.
2. Patients should be informed that blood pressure needs to be monitored regularly. If symptoms of elevated blood pressure or high measurements occur, contact a healthcare professional.
3. Patients should be informed that selpercatinib may cause QT interval prolongation. If any symptoms related to QT interval prolongation (such as syncope) occur, inform a healthcare professional.
from FDA，2024.06
